The NF-κB signaling pathway is misregulated in a variety of human diseases including many chronic inflammatory diseases and cancers (see www.nf-kb.org). As such, an understanding of the molecular details of NF-κB-dependent gene networks has implications for improved disease diagnoses and therapies.
CD10, also known as the common acute lymphocytic leukemia antigen (CALLA) or neutral endopeptidase (NEP), is a cell surface zinc metallo-endopeptidase (1, 2). CD10's ability to cleave signal peptides at the cell surface can affect cell proliferation, differentiation and migration (2) (3) (4) . Expression of CD10 can be used as a diagnostic marker for a variety of cancers (5) (6) (7) (8) (9) . Relevant to this study, CD10 is highly expressed in the germinal center B-cell (GCB) 2 molecular subtype of diffuse large B-cell lymphoma (DLBCL), whereas CD10 expression is low in the activated B-cell (ABC) subtype of DLBCL (8, 9) . ABC DLBCLs also have a high NF-κB gene expression profile and a poorer clinical prognosis as compared to GCB DLBCLs (10) . As such, reduced expression of CD10 and high NF-κB activity are both correlated with a less favorable DLBCL patient outcome (10) (11) (12) .
The correlation between high NF-κB activity and reduced CD10 expression has been observed in several other settings as well. We previously showed that over-expression of an activated mutant of the NF-κB family transcription factor REL in the GCB-like B-lymphoma cell line BJAB leads to reduced expression of CD10 (13) . Infection of cells with Epstein-Barr virus (EBV) or human cytomegalovirus, both inducers of NF-κB, causes reduced expression of CD10 (14, 15) . Taken together, such results suggested to us that NF-κB or a target of NF-κB is involved in repressing CD10 gene/protein expression in certain B-cell lymphomas.
Little is known about the control of CD10 transcription. Sequence analysis of the CD10 promoter/enhancer region revealed the presence of three consensus binding sites for transcription factor PU.1 (16) . PU.1 is a member of the Ets family of transcription factors and is required for proper B-cell development and differentiation (17) . Additionally, increased PU.1 expression has been correlated with the GCB subtype of DLBCL (8) . Therefore, we were interested in investigating whether PU.1 contributes to the regulation of CD10 expression in B-cell lymphoma.
In this report, we provide evidence for a functional link between activation of NF-κB and reduced expression of CD10. We show that activation of NF-κB in the GCB-like DLBCL cell line BJAB leads to reduced CD10 expression. Our data are consistent with a pathway in which NF-κB-induced up-regulation of microRNA miR-155 leads to down-regulation of PU.1 protein levels, and consequently, reduced levels of CD10. Moreover, we show that there is a correlation between high miR-155 expression and low PU.1/CD10 levels in a variety of B-lymphoma cell lines. These results are significant in that they reveal a molecular mechanism for downregulation of CD10, a key marker for predicting clinical response of patients with DLBCL.
EXPERIMENTAL PROCEDURES
Cell Culture, DNA Constructs and Stable Cell Line Generation-Human A293, A293T, Bosc23, BJAB, SUDHL-4, BL41, Daudi, IB4, RC-K8 and chicken DT40 cells (gift of Céline Gélinas, Ref. 18) , were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with either 10 or 20% heat-inactivated fetal bovine serum (FBS) (Biologos) as described (19) . The six human B-lymphoma cell lines used in this study are as follows: BJAB, EBV-negative, GCB-like DLBCL (20, 21) ; SUDHL-4, a B-lymphoma that has been characterized as both a follicular lymophoma (22) and GCB-like DLBCL (23); BL-41, EBV-negative Burkitt's lymphoma (14) ; Daudi, EBV-positive, LMP1-negative Burkitt's lymphoma (24) ; IB4, EBV-transformed lymphoblastoid cell line (14) ; and RC-K8, ABClike DLBCL (25) . For treatment of cells with lipopolysaccharide (LPS) (Sigma), BJAB cells were first cultured in DMEM containing 5% FBS for 24 h and then treated with 5 µg/ml of LPS for the indicated times.
All primers used in the study were purchased from Invitrogen and are described in Supplemental  Table S1 . pcDNA-PU.1 was a gift of Barbara Nikolajczyk (Boston University Medical School) and has been described previously (26) . To create pCD10-luc, a 717 bp region of the CD10 promoter, containing the three consensus PU.1 binding sites, was amplified by PCR from BJAB cell genomic DNA. The PCR product was digested with KpnI and XmaI, and this fragment was subcloned into the pGL3 promoter vector (Promega). For mutagenesis of the PU-1 site in the CD10 promoter, two overlapping primers were used that contained the desired mutations, as shown in Table S1 .
Transfections were performed using polyethylenimine (PEI) (Polysciences, Inc.). On the day of transfection, cells were washed twice with TD buffer (25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 ) and were then incubated with a plasmid DNA:PEI ratio of 1:3 in 300 µl DMEM for 15 min at room temperature. For transfection of Bosc23 cells with pSIREN and pVpack vectors, a plasmid DNA:PEI ratio of 2:3 in 300 µl DMEM was used. The DNA mixture was added to 2 ml (35-mm plate) or 4.5 ml (60-mm plate) of DMEM containing 10% FBS and this mixture was then added to the cells. The next day, the media was replaced with fresh DMEM containing 10% FBS. For reporter gene assays, cells were lysed 24 h later.
The retroviral vector pMSCV has been described previously (27) . pMSCVCARD11mut10 was created by subcloning a BamHI fragment containing the CARD11 mutant10 cDNA (a gift of Georg Lenz, National Cancer Institute) into BglII-digested pMSCV. pMSCV-BIC was created by subcloning a BsrGIEcoRI fragment from the BIC cDNA (a gift of Ricardo Aguiar, The University of Texas Health Science Center at San Antonio) into BsrGI-EcoRIdigested pMSCV. For over-expression of shRNAs, the retroviral vector pSIREN-RetroQ was used (a gift of Ulla Hansen, Boston University). The shRNA against HMGN1 (28) was excised from this vector and a BamHI-EcoRI fragment from the multiple cloning site of pSL1180 (Amersham) was subcloned in to create pSIREN-MCS. All shRNAs (Table S1 ) were ligated into pSIREN-MCS using the BamHI-EcoRI sites. The shRNA against PU.1 (29) and the control shRNA (30) have been previously described (also see Table S1 ). The retroviral, doxycylcine-inducible system has been previously described (31) . pRetroX-tight-CARD11mut10HA-Hyg was created by subcloning a BamHI/NotI fragment containing CARD11mut10 from the pMSCV-CARD11mut10 vector described above.
Virus stocks were generated by transfecting A293T cells with pMSCV, pMSCVCARD11mut10, pMSCV-BIC, pRetroX-tight-Hyg or pRetroX-tight-CARD11mut10HA-Hyg plus helper plasmid pcL10a1, as described previously (13, 27) . Virus stocks for pSIREN-RetroQ vectors were generated in Bosc23 cells using the helper vectors pVpack-GP and pVpack-VSV (28) . Two days later, virus was harvested. Two ml of virus (in the presence of 8 µg/ml polybrene) was used to infect 10 6 BJAB cells using the spin infection method (13) . Two days later, cells were selected with 2.5 µg/ml puromycin (Sigma) or 400 µg/ml hygromycin (Sigma), with fluid changing every five days in puromycin or hygromycin for 2-4 weeks.
Semi-quantitative Reverse Transcriptase PCR (RT-PCR) and Real-time PCR-Total RNA was isolated using TRIzol (Invitrogen). Semiquantitative RT-PCR was performed as described previously (32) with the primer sets listed in Table  S1 . Semi-quantitative RT-PCR for miR-155 and 5S ribosomal RNAs was performed by first reverse transcribing the RNA using specific stem loop primers which contain an annealing site for the universal reverse primer (Table S1 ) and the TaqMan miRNA Reverse Transcriptase kit (Applied Biosystems) as described previously (33) . miR-155 and 5S sequences were then amplified using a forward-specific primer and a universal reverse primer (Table S1 ). Real-time PCR was performed using the 7900HT Fast realtime PCR system (Applied Biosystems) with the Power SYBR Green PCR Master Mix (Applied Biosystems). Quantification of miR-155 RNA by real-time PCR was performed three times with triplicate samples and values were normalized to the 5S values. The final values represent relative expression (miR-155/5S) as compared to control samples.
Western Blotting-Western blotting was performed as described (25) . Whole cell extracts were prepared in AT buffer (20 mM HEPES, pH 7.9, 1 mM EDTA, 1 mM EGTA, 20 mM Na 4 P 2 O 7 , 1 mM DTT, 1% v/v Triton X-100, 20% w/v glycerol, 1 mM Na 3 VO 4 , 1 µg/ml PMSF, 1 µg/ml leupeptin, 1 µg/ml pepstatin). Samples were boiled in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 3.2% w/v SDS, 10% w/v glycerol, 5% v/v β-mercaptoethanol, 0.1% w/v bromophenol blue). Samples containing equal amounts of protein were separated on SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Micron Separation Inc.). Antibodies against PU.1 (sc-352), CD10 (sc-58939), HA (sc-805) and β-tubulin (sc-9104) were purchased from Santa Cruz Biotechnology. The BCL2 antibody was obtained from BD Transduction Laboratories (#610538). Anti-REL antiserum (#265) was a kind gift of Nancy Rice, and antiserum against v-Rel was described previously (27) . Nitrocellulose filters were incubated with primary antiserum for 2-18 h at room temperature or 4°C. The appropriate horseradish peroxidase-labeled secondary antiserum was added and immunoreactive proteins were detected with the SuperSignal Dura West Extended Duration Substrate chemiluminescence detection system (Pierce).
Electromobility Shift Assays (EMSAs)-EMSAs were performed using 10 µg of nuclear extract prepared from A293 cells, A293 cells transfected with pcDNA-PU.1, and BJAB cells stably transduced with MSCV, MSCV-CARD11mut10, or MSCV-RELΔTAD1 as described previously (13, 25) . Nuclear extracts were incubated with 2 µg poly(dI-dC), and [
32 P]-labeled PU.1 or NF-κB site probes (Table S1 ) in binding buffer (25 mM Tris-HCl, pH 7.4, 100 mM KCl, 0.5 mM EDTA, 6.25 mM MgCl 2 , 0.5 mM DTT, 10% w/v glycerol) in a final reaction volume of 50 µl, as previously described (25) . DNA-binding reactions were carried out for 30 min at room temperature. For supershifts, 3 µl of anti-PU.1 antibody (sc-352X, Santa Cruz Biotechnology) was incubated with the protein-DNA complexes for an additional 1 h on ice. Samples were resolved on 5% nondenaturing polyacrylamide gels. Gels were dried and protein-DNA complexes were detected by autoradiography.
Reporter Gene Assays-A293 cells in 35-mm plates were transfected with 1 µg of a pGL3-based CD10 promoter luciferase reporter plasmid (pCD10-luc or pCD10mutPU-1-luc), 0.5 µg of normalization plasmid pRSV-βgal and 0.5 µg of pcDNA or pcDNA-PU.1 using PEI, as described above. Luciferase activity was measured using the Luciferase Assay System according to manufacturer's instructions (Promega). Luciferase values were normalized to β-galactosidase values in all assays, as described previously (25) .
RESULTS

PU.1 and CD10 Protein Levels Are Inversely
Correlated with miR-155 Levels in Several BLymphoma Cell Lines-CD10 mRNA and protein levels are low in the less favorable ABC subtype of DLBCL (8, 9, 11, 12) , which also has increased NF-κB activity and increased levels of the NF-κB target gene product miR-155 (23, (34) (35) (36) (37) (38) , a microRNA that is processed from a non-coding RNA known as BIC (B-cell integration cluster gene). In contrast, GCB-like DLBCL primary tumors and cell lines express readily detectable levels of CD10 mRNA and protein, but have lower NF-κB activity and lower levels of miR-155 (13, 36, 37) . One direct target of miR-155 repression is the mRNA encoding transcription factor PU.1 (39, 40) .
Based on the above findings, we analyzed the levels of PU.1, CD10 and miR-155 among a panel of six B-lymphoma-like cell lines with varying levels of NF-κB-dependent gene expression. Two cell lines, IB4 (14) and RC-K8 (25) , have gene expression profiles consistent with high levels of NF-κB activity; four cell lines-BJAB (13, 21), SUDHL-4 (23), BL41 (41) and Daudi-are not known to have high NF-κB-driven gene expression. PU.1 and CD10 protein were expressed at readily detectable levels in the four cell lines with low NF-κB activity, whereas PU.1 and CD10 protein levels were extremely low in the high NF-κB activity IB4 and RC-K8 cell lines (Fig. 1A) . Moreover, as judged by qPCR, miR-155 was present at low levels in the four lymphoma cell lines with low NF-κB activity (Fig. 1B) . In contrast, miR-155 was present at increased levels in the high NF-κB activity IB4 and RC-K8 cell lines, which had miR-155 levels approximately 30-50 times higher than BJAB cells (Fig. 1B) . These results indicate that PU.1 and CD10 levels are low in transformed B-lymphoid cell lines where miR-155 levels and NF-κB activity are high (e.g., IB4, RC-K8).
PU.1 Binds to a Site in the CD10
Promoter to Increase Transcription-Based on this direct correlation between PU.1 and CD10 protein levels in six B-lymphoma-like cell lines and the presence of three consensus PU.1 binding sites (GAGGAA) in the CD10 upstream region (16; Fig. 2A ), we next sought to determine whether the CD10 gene might be a direct transcriptional target for PU.1. We first assessed the ability of PU.1 to bind to the CD10 promoter by performing EMSAs using DNA probes containing each of the three putative PU.1 binding sites (PU-1, PU-2, PU-3). Nuclear extracts were prepared from control A293 cells (Fig. 2B, lanes 2, 7, 12) or A293 cells overexpressing PU.1 (Fig. 2B, lanes 3, 8, 13 ), and these extracts were incubated with each of the three PU.1-site probes (PU-1, PU-2 or PU-3). We found that extracts from cells over-expressing PU.1 could specifically bind to the first PU.1 site (PU-1), whereas these extracts showed no binding to the PU-2 or PU-3 probes above the background binding seen with control A293 extracts (Fig. 2B) . Additionally, binding to the PU-1 site was competed by an excess of cold probe (Fig. 2B,  lane 4) , and the PU-1 site protein-DNA complex was supershifted by a PU.1-specific antibody (Fig.  2B, lane 5) .
To assess the ability of PU.1 to activate transcription from the CD10 promoter, we placed a portion of the CD10 promoter region containing the three consensus PU.1 binding sites upstream of a luciferase cassette (pCD10-luc). A293 cells were co-transfected with pCD10-luc and an expression plasmid for PU.1 or a vector control, and we then measured relative luciferase activity. Cotransfection of the PU.1 expression plasmid resulted in an approximately 6-fold increase in expression from pCD10-luc as compared to the vector control (Fig. 2C) . Mutation of the first PU.1 site (PU-1) in the CD10 promoter reduced the ability of PU.1 to transactivate the CD10 reporter plasmid by approximately 35% (Fig.  2C ). Western blotting confirmed that PU.1 was overexpressed in cells transfected with the pcDNA-PU.1 expression plasmid (Fig. 2C) .
Expression (Fig. 3A) . CD10 and PU.1 protein levels were both decreased in BJAB cells expressing HA-CARD11mut10 as compared to non-transduced BJAB or MSCV vector-transduced cells (Fig. 3A) . Consistent with CARD11mut10's ability to activate NF-κB (42), BCL2, a product of an NF-κB target gene and an ABC-like marker, showed increased protein expression in BJAB-CARD11mut10 cells (Fig.  3A) . Finally, miR-155 levels were increased by approximately 6-fold in BJAB-CARD11mut10 cells as compared to BJAB or BJAB-MSCV control cells (Fig. 3A ). To further demonstrate that CARD11mut10 protein expression could lead to reduced CD10 expression, we created an inducible expression system for CARD11mut10 protein (using a tet-ON retroviral transduction system [31] ) in BJAB cells. Induction of CARD11mut10 expression for seven days led to increased miR-155 and reduced CD10 protein (Fig. 3B) .
We next compared nuclear DNA-binding activity for PU.1 and NF-κB in BJAB-MSCV versus BJAB-CARD11mut10 cells (Fig. 3C) . Control BJAB-MSCV cells had considerable nuclear PU-1 site DNA-binding activity, which was clearly reduced in BJAB-CARD11mut10 cells. Conversely, nuclear NF-κB DNA-binding activity was increased in BJAB-CARD11mut10 cells as compared to control BJAB-MSCV cells, which is consistent with the reported ability of CARD11mut10 to activate NF-κB (42). As we previously showed (13), BJAB cells expressing an activated REL mutant (RELΔTAD1) also have increased levels of nuclear κB site DNA-binding activity (Fig. 3C) . The oncogenic NF-κB transcription factor vRel has recently been shown to up-regulate miR-155 (43) . Similar to our results in BJAB cells, expression of v-Rel in the avian DT40 Blymphoma cell line was also correlated with a reduction of PU.1 mRNA levels (Fig. 4E) .
CD10 Protein Levels Are Affected by Alterations in the Expression
CD10 Expression Is Down-regulated in BJAB Cells
Following Treatment with Lipopolysaccharide-NF-κB activity and miR-155 expression are both induced by LPS in macrophages (34, 44) . Therefore, to determine whether there is a normal association between activation of NF-κB and reduced expression of CD10, we treated BJAB cells with LPS, and then measured expression of miR-155 and CD10 as well as PU-1 site DNA-binding activity. Treatment of BJAB cells with LPS for 6 h caused a significant increase in BIC mRNA levels, as assessed by semi-quantitative RT-PCR, and BIC mRNA remained elevated after 24 h treatment (Fig. 5A ). REL and GAPDH mRNA levels remained unchanged following LPS treatment. By real-time PCR, we found that miR-155 levels increased by approximately 2-fold after 6 h of LPS treatment (Fig. 5B) and by approximately 3-fold at 24 h, as compared to untreated cells (Fig. 5B) .
LPS treatment of BJAB cells also led to a decrease in CD10 transcript levels within 6 h and these remained decreased at 24 h as assessed by RT-PCR (Fig. 5C) . Additionally, LPS treatment resulted in a time-dependent decrease in CD10 protein levels over a 72-h period (Fig. 5D) .
Finally, by EMSA, we found that BJAB cells treated with LPS for 72 h had decreased nuclear PU.1 DNA-binding activity as compared to untreated BJAB cells (Fig. 5E ).
DISCUSSION
In this report, we describe for the first time a molecular link between increased NF-κB activity and reduced expression of CD10, both of which are poor prognostic markers for B-cell lymphoma. Our results suggest that increased NF-κB activity in B-lymphoma cells can lead to increased expression of microRNA miR-155, which then causes decreased PU.1 protein levels and consequently, reduced transcription from the CD10 promoter (leading to reduced CD10 protein levels). Or, more simply, ↑NF-κB → ↑miR-155 → ↓PU.1 → ↓CD10. The evidence for and implications of this model are discussed below.
Expression of CD10, a cell surface zinc metalloendopeptidase, can be used to classify the two main molecular subtypes of DLBCL: CD10 is expressed at higher levels in patients with GCB DLBCL than in ones with ABC DLBCL (11, 12) . On the other hand, high nuclear NF-κB activity is associated with the ABC-subtype of DLBCL, which also carries a worse clinical outcome than GCB-subtype DLBCL, which has lower NF-κB activity (8, 23) . In this report, we demonstrate that increased NF-κB activity-as induced by expression of a lymphoma-derived mutant CARD11 protein or by LPS-leads to reduced CD10 levels in the GCB-like B-lymphoma cell line BJAB. Moreover, two B-lymphoma-like cell lines with high NF-κB activity (IB4, due to expression of the LMP1 protein of EBV [41] , and RC-K8, due to inactivating mutations in IκBα [25] ), express little to no CD10 protein (Fig. 1A) , whereas four B-lymphoma cell lines not known to have high NF-κB activity (BJAB [21] , SUDHL-4 (23), BL-41 [14] ; Daudi, [25, 45, 46] ) have high CD10 levels.
By immunocytochemistry, PU.1 and CD10 protein levels have been shown to have a positive correlation in several B-cell lymphomas (47) . By Western blotting, we also find a direct correlation between CD10 and PU.1 protein levels in six Blymphoma cell lines (Fig. 1A) . Moreover, CD10 protein expression and nuclear PU.1 DNA-binding activity in BJAB cells are considerably reduced by expression of CARD11mut10 (Fig. 3A, C) .
Our results show that PU.1 can activate a reporter plasmid containing sequences from the CD10 promoter (Fig. 2C) ; however, the sites required for this activation are not clear. There are three putative PU.1 binding sites in the promoter region of CD10 all containing the same core sequence GAGGAA (Fig 2A) ; however, PU.1 was only able to bind one of these predicted sites (PU-1) in vitro (Fig. 2B) . While the core sequence GAGGAA is known to be required for efficient PU.1 binding, bases outside of this core motif can also affect also proper PU.1 binding (48, 49) . Mutation of the PU-1 binding site only partially reduced PU.1-induced activation of the CD10 promoter (Fig 2C) , and mutation of all three predicted PU.1 consensus sites did not further reduce PU.1-induced transactivation (data not shown). The residual PU.1-induced activation of the CD10 promoter in the presence of a mutated PU-1 site may be mediated through non-consensus PU.1 binding sites in the CD10 promoter. Indeed, there are six AAGGAA sites within the CD10 promoter fragment we have used, and PU.1 has been shown to bind to some AAGGAA sequences (50, 51) . One of these AAGGAA sites (PU-4) is found within the first region of the CD10 promoter (nucleotides 1-470) and five of these sites are clustered in the second region of the promoter (nucleotides 449-717) (Fig. S1A) .
Reporter plasmids containing each region can be weakly induced by PU.1 (Fig. S1B) , and the sum of the PU.1-induced activation of each region of the CD10 promoter is approximately equal to the induction of the full 717 bp CD10 promoter region (Fig. S1B) . These results suggest that nonconsensus (AAGGAA) PU.1 sites play a role in PU.1-induced activation of CD10 transcription.
By several criteria, we show that high miR-155 levels correlate with activation of NF-κB and reduced levels of PU.1 and CD10 in B-lymphoma cell lines. First, transformed B-lymphoid cell lines with high NF-κB activity have high miR-155 levels and low PU.1 and CD10 levels, whereas Blymphoma cell lines with low NF-κB/miR-155 levels have increased levels of PU.1 and CD10 (Fig. 1) . Second, over-expression of miR-155 leads to reduced levels of PU.1 and CD10 in BJAB cells (Fig. 4A-C) . Third, miR-155 levels are up-regulated in BJAB cells by two inducers of NF-κB: expression of a lymphoma-derived, constitutively active CARD11 mutant (Fig. 3A) or by treatment with LPS (Fig. 5B) . Fourth, overexpression of v-Rel in the chicken B-lymphoma cell line DT40 leads to decreased PU.1 mRNA levels (Fig 4E) , and v-Rel has been shown to increase miR-155 expression (43) . Fifth, shRNAmediated knockdown of PU.1 leads to reduced CD10 protein levels in BJAB cells (Fig. 4D) . Our results are consistent with previous reports showing that miR-155 is up-regulated in macrophages in response to various cytokines or inducers of Toll-like receptors, including LPS (52) and that the EBV LMP1 protein can activate miR-155 expression through an NF-κB binding site in the BIC promoter (53) .
MicroRNAs base pair to the 3' UTR of target mRNAs, which cause translational repression, sometimes through mRNA degradation (54) . PU.1 mRNA has been shown to be directly targeted by miR-155 in B cells (40, 55) . Reduced PU.1 expression caused by miR-155 is important for the proper production of IgG1 antibodies (40) , and miR-155 knockout mice have a defect in the B-cell humoral response to antigen due to impaired germinal center formation (56, 57) . Moreover, PU.1 knockout mice have defects in the development of certain B-cell lineages (17) . In general, there is little known about the downstream transcriptional network of PU.1 or how the expression of PU.1 target genes is important in immune function and regulation. We now show that PU.1 can directly increase transcription from the CD10 promoter. CD10 acts to cleave peptides in the extracellular matrix and thus has been thought to regulate B cells by activating and/or repressing factors that promote differentiation (2) . Further investigation of CD10's role in the germinal center and its function in Bcell differentiation may help us gain insight into the normal function of miR-155-mediated regulation of PU.1.
Transgenic mice over-expressing miR-155 in B cells develop lymphoblastic leukemias and lymphomas (59) . Of note, these miR-155 transgenic mice also have an expanded population of B cells with low CD10 expression (58) . Moreover, elevated levels of miR-155 are present in various types of B-cell lymphoma (34) , including ABC-like DLBCL and, as we show here, the IB4 and RC-K8 cell lines (Fig. 1B) . Inhibition of NF-κB, which would be expected to reduce miR-155 expression, has been shown to specifically inhibit the proliferation of ABC-like DLBCL cell lines, including RC-K8 (23, 25) .
The results from the present study shed light on a B-lymphoma gene network controlled indirectly by NF-κB. This pathway is of particular interest because less clinically favorable DLBCLs (e.g., the ABC-subtype) can have several types of gene mutations that endow them with constitutive activation of NF-κB and reduced expression of CD10 (11, 42, 59, 60) . Future studies will aim to determine whether CD10 affects B-lymphoma pathogenesis and may also focus on determining whether the NF-κB->CD10 pathway is involved in other cancer types, given that CD10 is a prognostic marker for some types of solid tumors (6, 7). 
